Aurora Cannabis Inc. (ACB.TO)
CAD 6.11
(-4.83%)
CAD 6.11
(-4.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 20.47 Million CAD | 110.07% |
| 2022 | -203.31 Million CAD | -42.09% |
| 2021 | -143.08 Million CAD | -4.29% |
| 2020 | -137.2 Million CAD | 65.11% |
| 2019 | -393.23 Million CAD | -83.19% |
| 2018 | -214.66 Million CAD | -173.61% |
| 2017 | -78.45 Million CAD | -504.3% |
| 2016 | -12.98 Million CAD | -173.38% |
| 2015 | -4.74 Million CAD | 48.61% |
| 2014 | -9.24 Million CAD | -2997.78% |
| 2013 | -298.32 Thousand CAD | 25.87% |
| 2012 | -402.44 Thousand CAD | -21.82% |
| 2011 | -330.36 Thousand CAD | -78.23% |
| 2010 | -185.36 Thousand CAD | -224.15% |
| 2009 | -57.18 Thousand CAD | 60.43% |
| 2008 | -144.51 Thousand CAD | 36.77% |
| 2007 | -228.55 Thousand CAD | -18243.26% |
| 2006 | -1246.00 CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | 16.31 Million CAD | 307.41% |
| 2023 Q1 | 12.53 Million CAD | 739.74% |
| 2023 FY | - CAD | 110.07% |
| 2023 Q2 | -7.86 Million CAD | -162.72% |
| 2022 FY | - CAD | -42.09% |
| 2022 Q4 | -1.96 Million CAD | 87.69% |
| 2022 Q2 | -53.86 Million CAD | -40.5% |
| 2022 Q1 | -38.33 Million CAD | 38.06% |
| 2022 Q3 | -15.91 Million CAD | 70.45% |
| 2021 Q4 | -61.89 Million CAD | -18.56% |
| 2021 Q3 | -52.2 Million CAD | -73.91% |
| 2021 Q1 | 1.03 Million CAD | -30.45% |
| 2021 Q2 | -30.02 Million CAD | -2994.89% |
| 2021 FY | - CAD | -4.29% |
| 2020 Q1 | -14.62 Million CAD | 91.41% |
| 2020 Q2 | -2.1 Million CAD | 85.6% |
| 2020 Q3 | -121.96 Million CAD | -5691.31% |
| 2020 Q4 | 1.49 Million CAD | 101.22% |
| 2020 FY | - CAD | 65.11% |
| 2019 FY | - CAD | -83.19% |
| 2019 Q4 | -170.23 Million CAD | -225.21% |
| 2019 Q3 | -52.34 Million CAD | 38.92% |
| 2019 Q2 | -85.69 Million CAD | -78.05% |
| 2019 Q1 | -48.12 Million CAD | -176.04% |
| 2018 Q4 | 63.29 Million CAD | 143.23% |
| 2018 FY | - CAD | -173.61% |
| 2018 Q3 | -146.41 Million CAD | -196.95% |
| 2018 Q2 | -49.3 Million CAD | 44.28% |
| 2018 Q1 | -88.48 Million CAD | -146.36% |
| 2017 FY | - CAD | -504.3% |
| 2017 Q4 | -35.91 Million CAD | -24.83% |
| 2017 Q3 | -28.77 Million CAD | -104.15% |
| 2017 Q2 | -14.09 Million CAD | -802.88% |
| 2017 Q1 | -1.56 Million CAD | 76.41% |
| 2016 Q1 | -3.08 Million CAD | 57.1% |
| 2016 Q2 | -1.96 Million CAD | 36.37% |
| 2016 Q3 | -1.31 Million CAD | 33.19% |
| 2016 Q4 | -6.61 Million CAD | -404.01% |
| 2016 FY | - CAD | -173.38% |
| 2015 Q1 | -1.05 Million CAD | -103.65% |
| 2015 Q3 | 2.79 Million CAD | 246.54% |
| 2015 Q2 | 805.75 Thousand CAD | 176.05% |
| 2015 Q4 | -7.19 Million CAD | -357.8% |
| 2015 FY | - CAD | 48.61% |
| 2014 Q2 | -5.71 Million CAD | -1048.38% |
| 2014 Q4 | 29 Million CAD | 3371.48% |
| 2014 Q3 | -886.59 Thousand CAD | 84.47% |
| 2014 Q1 | -497.25 Thousand CAD | -277.0% |
| 2014 FY | - CAD | -2997.78% |
| 2013 FY | - CAD | 25.87% |
| 2013 Q2 | -30.7 Thousand CAD | 25.6% |
| 2013 Q3 | -94.46 Thousand CAD | -207.69% |
| 2013 Q4 | -131.89 Thousand CAD | -39.63% |
| 2013 Q1 | -41.26 Thousand CAD | 61.48% |
| 2012 Q1 | -148.61 Thousand CAD | 30.37% |
| 2012 Q3 | -75.09 Thousand CAD | -6.73% |
| 2012 FY | - CAD | -21.82% |
| 2012 Q2 | -70.36 Thousand CAD | 52.65% |
| 2012 Q4 | -107.13 Thousand CAD | -42.66% |
| 2011 Q1 | -44.41 Thousand CAD | 58.32% |
| 2011 Q4 | -213.45 Thousand CAD | -415.29% |
| 2011 FY | - CAD | -78.23% |
| 2011 Q2 | -38.75 Thousand CAD | 12.74% |
| 2011 Q3 | -41.42 Thousand CAD | -6.88% |
| 2010 Q4 | -106.56 Thousand CAD | -185.07% |
| 2010 Q1 | -37.64 Thousand CAD | 39.08% |
| 2010 Q2 | -43.49 Thousand CAD | -15.53% |
| 2010 FY | - CAD | -224.15% |
| 2010 Q3 | -37.38 Thousand CAD | 14.04% |
| 2009 FY | - CAD | 60.43% |
| 2009 Q4 | -61.79 Thousand CAD | -352.57% |
| 2009 Q3 | -13.65 Thousand CAD | -3.8% |
| 2009 Q2 | -13.15 Thousand CAD | 46.99% |
| 2009 Q1 | -24.81 Thousand CAD | -43.29% |
| 2008 Q4 | -17.31 Thousand CAD | 41.03% |
| 2008 Q2 | -32.19 Thousand CAD | 65.07% |
| 2008 FY | - CAD | 36.77% |
| 2008 Q3 | -29.36 Thousand CAD | 8.79% |
| 2008 Q1 | -92.15 Thousand CAD | -129.03% |
| 2007 Q3 | -22.09 Thousand CAD | 86.59% |
| 2007 Q1 | -1425.00 CAD | 0.0% |
| 2007 Q4 | -40.23 Thousand CAD | -82.07% |
| 2007 Q2 | -164.79 Thousand CAD | -11464.7% |
| 2007 FY | - CAD | -18243.26% |
| 2006 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Avicanna Inc. | -7.35 Million CAD | 378.351% |
| Avant Brands Inc. | 4.83 Million CAD | -323.366% |
| Cardiol Therapeutics Inc. | -27.87 Million CAD | 173.436% |
| Crescita Therapeutics Inc. | 45 Thousand CAD | -45397.778% |
| Knight Therapeutics Inc. | 40.89 Million CAD | 49.938% |
| MediPharm Labs Corp. | -10.47 Million CAD | 295.4% |
| OrganiGram Holdings Inc. | -207.61 Million CAD | 109.861% |
| Canopy Growth Corporation | -312.82 Million CAD | 106.545% |
| Willow Biosciences Inc. | -11.06 Million CAD | 285.101% |
| Auxly Cannabis Group Inc. | -10.82 Million CAD | 289.136% |